Eli Lilly Reports Mixed Q4 Results as Key Drug Sales Fall Short of Expectations

The pharmaceutical giant saw strong demand for its diabetes and weight-loss drugs but missed revenue estimates due to lower realized prices and inventory issues.

Eli Lilly's Q4 2024 revenue rose 45% year-over-year to $13.53 billion but fell short of analysts' expectations of $13.57 billion.
Adjusted earnings per share reached $5.32, surpassing the $4.95 forecast by analysts, driven by strong demand for key products.
Sales of weight-loss drug Zepbound and diabetes treatment Mounjaro, though growing, underperformed expectations for the second consecutive quarter due to lower realized prices and inventory adjustments.
The company reaffirmed its 2025 sales guidance of $58 billion to $61 billion and profit guidance of $22.05 to $23.55 per share, aligning with Wall Street projections.
Eli Lilly plans to release late-stage data on its next-generation obesity drug, retatrutide, later this year, which could offer a new approach to appetite and blood sugar regulation.

Investor's Business Daily

Benzinga